Order a Test​

New discoveries are increasing the number of biomarker/drug associations at an unprecedented rate. It is more important than ever for cancer patients to have comprehensive molecular testing on their tumors. The section below describes the breadth of testing provided by the Molecular Intelligence profile, ensuring that these discoveries are at the forefront of patient care. ​

MI Profile

Comprehensive Tumor Profiling

The Caris Molecular Intelligence® comprehensive tumor profiling approach to assess DNA, RNA and proteins reveals a molecular blueprint to guide more precise and individualized treatment decisions from about 60+ FDA-approved therapies.

icon_DNA

DNA

Whole Exome Sequencing
(Mutations, Indels & Copy Number Alterations)

icon_RNA

RNA

Whole Transcriptome Sequencing
(Fusions & Variant Transcripts)

icon_Protein

Protein

Immunohistochemistry

Biomarker Analysis by Tumor Type

The information below details the biomarkers analyzed by technology for the tumor type submitted. Before ordering testing services, please refer to this profile menu to view the most-up-to date listing of biomarkers that will be performed. Tests may vary if samples with insufficient tissue are submitted.

All Biomarker Analysis includes:

Whole Exome Sequencing (WES)

DNA
Genomic Signatures
Point Mutations
Indels
Copy Number Alterations
MSI
TMB
LOH

Whole Transcriptome Sequencing (WTS)

RNA
Genomic Signatures
Fusion Analysis
Variant Transcripts
HLA*
 
*Not available in New York

Additional Testing:

Select tumor type to see specific tests to be performed.

Tumor Type:
No tumor selected

Additional Information:

  • Caris applies the appropriate tumor-specific customizations standard with every MI Profile test order.
  • In certain instances, some biomarkers included in MI Profile or genes ordered individually will not associate with commercially available cancer therapies or clinical trials.
  • For PD-L1 IHC testing, Dako antibodies 22c3, 28-8 and antibody SP-142 are used as appropriate.
  • For certain patients, HER2 testing is performed by Chromogenic in situHybridization, in addition to Next-Generation Sequencing.
  • For certain patients, MSI testing is performed by Fragment Analysis.
REFLEX TESTING MENU >
Need Support?
Contact Us
or call 1.888.979.8669 (international: +41 21 533 53 00)